肿瘤预防与治疗2016，Vol.29Issue(1)：12-16,5.DOI:10.3969/j.issn.1674-0904.2016.01.003
吉西他滨联合紫杉醇方案与长春瑞滨单药方案治疗蒽环类耐药的转移性乳腺癌的临床观察
Gemcitabine plus Paclitaxel Regimen and Vinorelbine Single Agent Regimen for Anthracycline-resistant Metastatic Breast Cancer
张杰 1徐可 1王少龙1
作者信息
- 1. 成都医学院第一附属医院，成都 610500
- 折叠
摘要
Abstract
Objective:To evaluate the difference in curative effect and adverse events between gemcitabine plus paclitaxel regimen and vinorelbine single agent regimen in treating anthracycline-resistant metastatic breast cancer patients. Methods:From Oct.2009 to Dec.2012,126 cases of metastatic breast cancer who met the criterion we established for this study were collected and randomized into gemcitabine plus paclitaxel group (GT group)and vinorelbine group (NVB group).The observation end points included response rate (RR),disease control rate (DCR),progression-free survival (PFS),overall survival (OS)and adverse events.Chi-square test was used to compare the RR,DCR and adverse events in both groups and Kaplan-Meier method was used to estimate the survival rate in both arms.Log-rank test was used to compare the survival rate of each group.Results:GT group,compared with NVB group,had better results in RR and OS and the differences were statistically significant (P =0.033;P =0.013).The results in DCR and PFS,however,had no statistically significant difference (P =0.440;P =0.159).GT group had more grade 3 ~4 adverse events of leucopenia (P=0.025),more grade 1 ~2 adverse events of nausea and vomiting (P =0.035),constipation (P =0.030),myalgia or arthralgia (P =0.000)and fatigue (P =0.003).Conclusion:Compared to NVB regimen,GT regimen may increase the RR and OS in patients of better physical condition but we should pay more attention to the adverse events.关键词
吉西他滨联合紫杉醇/长春瑞滨/蒽环类耐药/转移性乳腺癌Key words
Gemcitabine plus Paclitaxel/Vinorelbine/Anthracycline-resistant/Metastatic Breast Cancer分类
医药卫生引用本文复制引用
张杰,徐可,王少龙..吉西他滨联合紫杉醇方案与长春瑞滨单药方案治疗蒽环类耐药的转移性乳腺癌的临床观察[J].肿瘤预防与治疗,2016,29(1):12-16,5.
